论文部分内容阅读
目的对比培美曲塞联合奥沙利铂与吉西他滨联合奥沙利铂治疗老年晚期肺腺癌的临床疗效和毒副作用。方法以入院顺序将83例老年晚期肺腺癌患者编号,42例单号为吉西他滨组,给予吉西他滨联合奥沙利铂治疗,41例双号为培美曲塞组,给予培美曲塞联合奥沙利铂治疗,均化疗21d为1个周期,至少化疗2个周期以上,评价两组患者的近期疗效和药物对机体的毒副作用。结果培美曲塞组总有效率26.83%与吉西他滨组21.43%比较,P>0.05;培美曲塞组在胃肠反应、骨髓抑制和神经毒性等毒副作用发生率明显低于吉西他滨组,P<0.05。结论培美曲塞联合奥沙利铂治疗老年晚期肺腺癌疗效确切,毒副作用小,是一种更适合老年患者的化疗方案,值得临床继续研究和探讨。
Objective To compare the clinical efficacy and side effects of pemetrexed combined with oxaliplatin and gemcitabine plus oxaliplatin in the treatment of elderly patients with advanced lung adenocarcinoma. Methods A total of 83 elderly patients with advanced lung adenocarcinoma were enrolled in this study. Forty-two patients were treated with gemcitabine combined with oxaliplatin, 42 patients were treated with pemetrexed, Saliva platinum treatment, both 21d for a cycle of chemotherapy, chemotherapy for at least 2 cycles, the evaluation of the two groups of patients with short-term efficacy and drug side effects on the body. Results The total effective rate of pemetrexed group was 26.83% compared with 21.43% of gemcitabine group, P> 0.05. The incidence of toxic and side effects such as gastrointestinal reaction, myelosuppression and neurotoxicity in pemetrexed group was significantly lower than that in gemcitabine group (P < 0.05. Conclusion pemetrexed combined with oxaliplatin in the treatment of elderly patients with advanced lung adenocarcinoma has definite curative effect and small toxic and side effects. It is a more suitable chemotherapy regimen for elderly patients and deserves further clinical research and discussion.